LILLY ELI & PHARMACEUTICAL DIV -- QA371U VINBLASTINE SULFATE
=======================================================
Material Safety Data Sheet
=======================================================
MSDS Num: BXPKB
MSDS NAME: QA371U VINBLASTINE SULFATE
Responsible Party
Name: LILLY ELI & CO PHARMACEUTICAL DIV
Address: 307 E MCCARTY ST
City: INDIANAPOLIS IN 48285-5000
Info Phone: 317-276-2000/317-276-3494
Emergency Phone Number: 317-276-2000/317-276-3494
Review Ind: Y
Published: Y
=======================================================
Preparer Co. when other than Responsible Party Co.
=======================================================
Assigned Ind: Y
Name: LILLY ELI & CO PHARMACEUTICAL DIV
Address: LILLY CORPORATE CENTER
City: INDIANAPOLIS IN 46285
=======================================================
Contractor Summary
=======================================================
Name: LILLY ELI & CO PHARMACEUTICAL DIV
Address: LILLY CORPORATE CENTER
City: INDIANAPOLIS IN 46285
Phone: 317-276-2000
Name: LILLY ELI AND CO PHARMACEUTICAL DIV
Address: LILLY CORPORATE CENTER
City: INDIANAPOLIS IN 46285
Phone: 317-276-2000
=======================================================
Ingredients
=======================================================
Cas: 143-67-9
RTECS #: YY8400000
Name: VINBLASTINE SULFATE
=======================================================
Health Hazards Data
=======================================================
Route Of Entry Inds - Inhalation: YES
Skin: YES
Ingestion: YES
Carcinogenicity Inds - NTP: NO
IARC: NO
OSHA: NO
Effects of Exposure: VINBLASTINE SULFATE: SKIN IRRITANT. DEPIGMENTATION. EYES:
SEVERE IRRITATION. DIRECT CONTACT MAY INTERFERE W/THE REPRODUCTION OF THE
CORNEAL EPITHELIUM. SOME PATIENTS TREATED HAVE DEVELOPED SECOND MALI GNANCIES
& DECREASE IN FERTILITY. INHALATION: POWDER EXPECTED TO CAUSE LOCAL
IRRITATION OF THE NOSE & THROAT. (SEE SUPP)
Explanation Of Carcinogenicity: NONE
Signs And Symptions Of Overexposure: IRRITATION, TEARING, PAIN, BLURRED VISION,
DELAYED BURN, SCARRING
First Aid: EYES: FLUSH W/A STEADY, GENTLE STREAM OF WATER FOR 15 MINS. SKIN:
WASH W/PLENTY OF SOAP & WATER. INHALATION: MOVE TO FRESH AIR. IF NOT
BREATHING, GIVE CPR. INGESTION: DON'T INDUCE VOMITING. OBTAIN MED ICAL
ATTENTION IN ALL CASES. NOTE TO PHYSICIAN: A STEROID EYE OINTMENT/DROPS SERVE
TO MINIMIZE INFLAMMATION.
=======================================================
Handling and Disposal
=======================================================
Spill Release Procedures: USE EITHER WET CLEAN-UP METHODS, USE APPROPRIATE
VACUUM CLEANERS HAVING HIGH EFFICIENCY PARTICULATE (HEPA) FILTERS. USE DOUBLE
PAIRS OF LATEX DISPOSABLE GLOVES DISPOSING OF WITHIN AN HOUR, GOGGLES & N
IOSH APPROVED DUST/MIST RESPIRATOR.
Waste Disposal Methods: TO BE DECOMPOSED USING A BASIC (PH OF 10) SODIUM
HYPOCHLORITE SOLUTION. PLACE RESIDUE IN A SEGREGATED, SEALED PLASTIC
CONTAINER. DISPOSE OF IN CHEMICAL LANDFILL/BY INCINERATION
1562F-SOLIDS/1742-FOR LIQUIDS IAW/LOCAL/STATE/FEDERAL REGULATIONS.UN1544
Handling And Storage Precautions: IN PRODUCTION SETTINGS, USE AN
AIRLINE-SUPPLIED HOOD-TYPE RESPIRATOR. HAND-TO-EYE CONTACT MUST BE
ELIMINATED.
Other Precautions: AVOID SKIN/EYE CONTACT.
=======================================================
Fire and Explosion Hazard Information
=======================================================
Extinguishing Media: WATER, CO2, DRY CHEMICAL, FOAM/HALON
Unusual Fire/Explosion Hazard: MAY FORM DUST MIXTURES IN AIR WHICH COULD
EXPLODE IF SUBJECTED TO AN IGNITION SOURCE.
=======================================================
Control Measures
=======================================================
Respiratory Protection: REQUIRED
Ventilation: EXTENSIVE LOCAL EXHAUST/ENCLOSED PROCESS EQUIPMENT.
Protective Gloves: NATURAL RUBBER LATEX
Eye Protection: CHEMICAL GOGGLES/FACE SHIELD
Other Protective Equipment: SAFETY GLASSES, FULL FACE MASK, LONG SLEEVES,BODY
COVERING
Work Hygienic Practices: REMOVE/LAUNDER CONTAMINATED CLOTHING BEFORE REUSE.
Supplemental Safety and Health: HEALTH HAZ CONT'D: MAY HAVE EFFECTS SUCH AS;
NERVOUS SYSTEM (COMA), HEART-(DECREASED BLOOD PRESSURE) BLOOD-(DECREASED
WHITE BLOOD CELLS), EXTRAMEDULLARY HEMATOPOIESIS), (BONE MARROW HYPERPLASIA,
DECR EASED BONE MARROW MYELOID CELLS). VINBLASTINE SULFATE IS A CYTOTOXIC
MATERIAL.
=======================================================
Physical/Chemical Properties
=======================================================
PH: 3.5-5
Solubility in Water: COMPLETE
Appearance and Odor: WHITE/OFF-WHITE POWDER W/NO ODOR
=======================================================
Reactivity Data
=======================================================
Stability Indicator: YES
Materials To Avoid: STRONG OXIDIZING AGENTS; PEROXIDES, PERMANGANATES, NITRIC
ACID & STRONG BASES
Hazardous Decomposition Products: TOXIC FUMES
Hazardous Polymerization Indicator: NO
=======================================================
Toxicological Information
=======================================================
=======================================================
Ecological Information
=======================================================
=======================================================
MSDS Transport Information
=======================================================
=======================================================
Regulatory Information
=======================================================
=======================================================
Other Information
=======================================================
=======================================================
HAZCOM Label
=======================================================
MSDS NAME: QA371U VINBLASTINE SULFATE
Assigned IND: Y
Company: LILLY ELI & CO PHARMACEUTICAL DIV
Street: LILLY CORPORATE CENTER
City: INDIANAPOLIS IN
Zipcode: 46285
Health Emergency Phone: 317-276-2000/317-276-3494
Label Required IND: Y
Date Of Label Review: 12/16/1998
Status Code: C
Label Date: 12/16/1998
Origination Code: G
Hazard And Precautions: VINBLASTINE SULFATE: SKIN IRRITANT. DEPIGMENTATION.
EYES: SEVERE IRRITATION. DIRECT CONTACT MAY INTERFERE W/THE REPRODUCTION OF
THE CORNEAL EPITHELIUM. SOME PATIENTS TREATED HAVE DEVELOPED SECOND MALI
GNANCIES & DECREASE IN FERTILITY. INHALATION: POWDER EXPECTED TO CAUSE
LOCAL IRRITATION OF THE NOSE & THROAT. (SEE SUPP)IRRITATION, TEARING,
PAIN, BLURRED VISION, DELAYED BURN, SCARRING
=======================================================
Disclaimer (provided with this information by the compiling agencies): This
information is formulated for use by elements of the Department of Defense.
The United States of America in no manner whatsoever expressly or implied
warrants, states, or intends said information to have any application, use or
viability by or to any person or persons outside the Department of Defense
nor any person or persons contracting with any instrumentality of the United
States of America and disclaims all liability for such use. Any person
utilizing this instruction who is not a military or civilian employee of the
United States of America should seek competent professional advice to verify
and assume responsibility for the suitability of this information to their
particular situation regardless of similarity to a corresponding Department
of Defense or other government situation.
*** END OF RECORD *** |
|
|